View Information Collection Request (ICR) Package
Skip to main content
An official website of the United States government
The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Search:
Agenda
Reg Review
ICR
This script is used to control the display of information in this page.
Display additional information by clicking on the following:
All
Brief and OIRA conclusion
Abstract/Justification
Legal Statutes
Rulemaking
FR Notices/Comments
IC List
Burden
Misc.
Common Form Info.
Certification
View Information Collection (IC) List
View Supporting Statement and Other Documents
Please note that the OMB number and expiration date may not have been determined when this Information Collection Request and associated Information Collection forms were submitted to OMB. The approved OMB number and expiration date may be found by clicking on the Notice of Action link below.
View ICR - OIRA Conclusion
OMB Control No:
0938-1051
ICR Reference No:
200910-0938-005
Status:
Historical Active
Previous ICR Reference No:
200809-0938-004
Agency/Subagency:
HHS/CMS
Agency Tracking No:
Title:
Medicare Advantage and Prescription Drug Program: Final Marketing Provisions CFR 422.111(a)(3) and 423.128 (a)(3)
Type of Information Collection:
Revision of a currently approved collection
Common Form ICR:
No
Type of Review Request:
Regular
OIRA Conclusion Action:
Approved with change
Conclusion Date:
08/03/2010
Retrieve Notice of Action (NOA)
Date Received in OIRA:
10/16/2009
Terms of Clearance:
As with previous ICRs under this control number, because this collection appears to require adjustments on an annual basis, this collection is approved for 12 months.
Inventory as of this Action
Requested
Previously Approved
Expiration Date
08/31/2011
36 Months From Approved
08/31/2010
Responses
740
0
670
Time Burden (Hours)
8,880
0
8,040
Cost Burden (Dollars)
0
0
0
Abstract:
This final rule implements provisions of the Social Security Act (the Act) establishing and regulating the Medicare Advantage (MA) program. The MA program was enacted in Title II of The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) on December 8, 2003. The MA program replaces the Medicare+Choice (M+C) program established under Part C of the title XVIII of the Act, while retaining most key features of the M+C program. The MA program attempts to broadly reform and expand the availability of private health plan options to Medicare beneficiaries. Medicare Advantage (MA) organizations and Prescription Drug Plan Sponsors use the information to comply with the eligibility requirements and the MA and Part D contract requirements. CMS will use this information to ensure that correct information is disclosed to Medicare beneficiaries, both potential enrollees and enrollees.
Authorizing Statute(s):
PL:
Pub.L. 110 - 275 103
Name of Law: The Medicare Improvements for Patients and Providers Act of 2008
PL:
Pub.L. 108 - 117 201
Name of Law: The Medicare Prescription Drug, Improvement, and Modernization Act of 2003
Citations for New Statutory Requirements:
None
Associated Rulemaking Information
RIN:
Stage of Rulemaking:
Federal Register Citation:
Date:
0938-AP24
Final or interim final rulemaking
73 FR 54208
09/18/2008
Federal Register Notices & Comments
60-day Notice:
Federal Register Citation:
Citation Date:
74 FR 34758
07/17/2009
30-day Notice:
Federal Register Citation:
Citation Date:
74 FR 48972
09/25/2009
Did the Agency receive public comments on this ICR?
No
Number of Information Collection (IC) in this ICR:
1
IC Title
Form No.
Form Name
Medicare Advantage and Prescription Drug Benefit Program: Final Marketing Provisions referenced in 42 CFR 422.111(a)(3) and 423.128(a)(3)
CMS-10260-MAOP, CMS-10260-CP, CMS-10260- MAPDP, CMS-10260-PDP's, CMS-10260-, CMS-10260-PPO
Annual Notice of Change & Evidence of Coverage for Medicare Advantage Only Plans
,
Annual Notice of Change & Evidence of Coverage for Cost Plans
,
Annual Notice of Change & Evidence of Coverage for Medicare Advantage Prescription Drug Plans
,
Annual Notice of Change & Evidence of Coverage for Prescription Drug Plans
,
Annual Notice of Change & Evidence of Coverage for Provider Fee‐for‐Service Plans
,
Annual Notice of Change & Evidence of Coverage for Preferred Provider Organizations
ICR Summary of Burden
Total Approved
Previously Approved
Change Due to New Statute
Change Due to Agency Discretion
Change Due to Adjustment in Estimate
Change Due to Potential Violation of the PRA
Annual Number of Responses
740
670
0
70
0
0
Annual Time Burden (Hours)
8,880
8,040
0
840
0
0
Annual Cost Burden (Dollars)
0
0
0
0
0
0
Burden increases because of Program Change due to Agency Discretion:
Yes
Burden Increase Due to:
Miscellaneous Actions
Burden decreases because of Program Change due to Agency Discretion:
No
Burden Reduction Due to:
Short Statement:
The change of burden is associated with the MIPPA disclosure and dissemination requirements which were modified for MA organizations and Part D sponsors.
Annual Cost to Federal Government:
$17,098
Does this IC contain surveys, censuses, or employ statistical methods?
No
Is the Supporting Statement intended to be a Privacy Impact Assessment required by the E-Government Act of 2002?
No
Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]?
No
Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]?
Uncollected
Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)?
No
Is this ICR related to the Pandemic Response?
Uncollected
Agency Contact:
Bonnie Harkless 4107865666
Common Form ICR:
No
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(a) It is necessary for the proper performance of agency functions;
(b) It avoids unnecessary duplication;
(c) It reduces burden on small entities;
(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;
(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;
(f) It indicates the retention periods for recordkeeping requirements;
(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.
(i) It uses effective and efficient statistical survey methodology (if applicable); and
(j) It makes appropriate use of information technology.
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
Certification Date:
10/16/2009
Something went wrong when downloading this file. If you have any questions, please send an email to risc@gsa.gov.